June 21, 2017

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older

Key Points

Key points are not available for this paper at this time.

Abstract

RIV4 provided better protection than standard-dose IIV4 against confirmed influenza-like illness among older adults. (Funded by Protein Sciences; ClinicalTrials.gov number, NCT02285998 .).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Lisa M. Dunkle

Ruvim Izikson

P. Patriarca

Journals

New England Journal of Medicine

Actions

Institutions

BioSciCon (United States)

Jean Brown Research

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study